Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Last trade$0.4901
Day change-$0.03 (-5.77%)
Day range$0.482 – $0.565
Volume703,580
Market cap$38M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$37.79M
Price / earnings
—
Price / book
4.98×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.23×
Profitability
Earnings per share
-$0.31
Return on assets
-79.42%
Return on equity
-294.15%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.17×
Quick ratio
2.17×
Cash ratio
2.07×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$44.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BMEA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.43M
$3.62M
$3.65M
$3.6M
$4.2M
$4.71M
$6.82M
$4.83M
Research and development
$8.53M
$9.14M
$9.12M
$8.12M
$14.4M
$16.57M
$22.9M
$25.24M
Total operating expenses
$12.96M
$12.77M
$12.77M
$11.72M
$20.81M
$21.28M
$29.71M
$30.07M
Operating income
-$12.96M
-$12.77M
-$12.77M
-$11.72M
-$20.81M
-$21.28M
-$29.71M
-$30.07M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$6.18M
-$8.33M
-$12.42M
$4.61M
-$16.41M
-$20.74M
-$29.26M
-$29.3M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.18M
-$8.33M
-$12.42M
$4.61M
-$16.41M
-$20.74M
-$29.26M
-$29.3M
Net income attributable to common shareholders
-$6.18M
-$8.33M
-$12.42M
$4.61M
-$16.41M
-$20.74M
-$29.26M
-$29.3M
EBITDA
-$12.95M
-$12.75M
-$12.73M
-$11.67M
-$18.17M
-$20.81M
-$29.24M
-$29.61M
Basic earnings per share
-$0.09
-$0.12
-$0.17
$0.06
-$0.27
-$0.51
-$0.80
-$0.81
Diluted earnings per share
-$0.09
-$0.12
-$0.17
$0.06
-$0.27
-$0.51
-$0.80
-$0.81
Recent news
Company coverage with links to the original publishers.
Biomea Fusion presented clinical and translational data for icovamenib at the ADA 86th Scientific Sessions, demonstrating improvements in HbA1c and C-peptide levels in type 1 and type 2 diabetes patients, along with potential benefits for muscle preservation and fat reduction. The company also expanded its Phase I BMF-650 study to evaluate rapid titration schedules for its oral GLP-1 receptor agonist candidate.
Biomea Fusion reported Q1 2026 net loss of $12.4 million, down significantly from $29.3 million in Q1 2025, driven by reduced R&D and G&A expenses following headcount reductions. The company announced positive 52-week data from its Phase II COVALENT-112 trial showing icovamenib achieved a 52% increase in C-peptide levels in recently diagnosed type 1 diabetes patients with durability through Week 52. Two Phase II type 2 diabetes trials (COVALENT-211 and COVALENT-212) are enrolling with topline data expected in Q4 2026, while the Phase I obesity trial (GLP-131) is on track with initial weight reduction data expected in Q2 2026. Cash runway is projected into Q1 2027.
Biomea Fusion announced that three abstracts on icovamenib, its investigational oral menin inhibitor, have been selected for late-breaking poster presentations at the ADA 86th Scientific Sessions in June 2026. The presentations will showcase data from Phase 2 trials (COVALENT-111 and COVALENT-112) demonstrating icovamenib's potential to improve beta cell function and insulin secretion in both type 1 and type 2 diabetes patients, including those on background GLP-1 therapy.
Biomea Fusion announced the first patient dosing in two Phase II clinical trials (COVALENT-211 and COVALENT-212) evaluating icovamenib for type 2 diabetes patients failing standard-of-care therapies. COVALENT-211 targets insulin-deficient T2D patients, while COVALENT-212 targets patients uncontrolled on GLP-1 receptor agonists. Both studies will enroll approximately 60 patients each, with topline 26-week primary endpoint data anticipated in Q4 2026. The trials build on positive Phase II COVALENT-111 data showing durable HbA1c reductions of up to 1.8% that persisted nine months post-treatment.
Biomea Fusion announced positive 52-week follow-up results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes patients. The drug demonstrated durable efficacy nine months post-dosing, with severe insulin-deficient diabetes patients achieving a 1.2% HbA1c reduction at Week 52. The company maintained a favorable safety profile and plans to advance two new Phase II studies targeting specific patient populations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.